Kornimate/medical-research-clean huggingface dataset:
evaluating the efficacy and results of endoscopic gastroplasty performed using overstitch in patients with obesity.

Conditions: Obesity

Summary: obesity is a chronic disease that has grown to epidemic characteristics in brazil and around the world in recent years. treatment for patients with class iii or class ii obesity with comorbidities is already well established, with bariatric surgery being the best option. however, there is no consensus as to the best treatment for cases of class i and class ii obesity without comorbidities. the objective of this research will be to make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures. the procedures will be performed at the endoscopy service of the mario covas hospital in são paulo, sp. data collection will be performed at the same location.

the objective of this research will be to make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures. the secondary objective will be to correlate demographic, endoscopic and laboratory data with the results of this procedure. patients and methods: patients with class i obesity with or without comorbidities and patients with class ii obesity without comorbidities, irrespective of gender and ethnic background, from the state of são paulo and other states of the country will be submitted to vertical endoscopic gastroplasty. the procedures will be performed at the endoscopy service of the mario covas hospital in são paulo, sp. data collection will be performed at the same location. information will be obtained during the outpatient follow-up at the hospital mario covas including demographic (gender, age), clinical (height, weight, time after procedure, systemic arterial hypertension, diabetes, dyslipidemia, smoking, alcohol consumption) and operative data (complications). preparation for the procedure: all the exams will be performed at the hospital mario covas after the patients have fasted for at least 8 hours. the procedure will begin with the patient in left lateral decubitus under general anesthesia performed by an anesthesiologist. endoscopic sutures will be performed using 2-0 prolene thread until a tubular-shaped stomach is formed similar to a vertical gastrectomy. recovery after the procedure: after the procedure and recovery from anesthesia, all patients will be discharged but only together with a companion. all patients will receive guidance and will remain in touch with a physician to report any adverse signs or symptoms. outcomes primary outcome: to confirm the efficacy of endoscopic sutures in the primary treatment of obesity. secondary outcome: to evaluate the use of the endoscopic sutures in relation to demographic data.

Eligibility criteria:
inclusion criteria: * bmi \> 30 and \< 36 with or without comorbidities * bmi \> 36 and \< 40 without comorbidities exclusion criteria: * prior gastric surgery * use of anticoagulants * psychiatric disorders * severe esophagitis
the effect of poorly designed school furniture on children's head and scapulae postures

Conditions: Ergonomics

Summary: investigate the compatibility of school furniture design


Eligibility criteria:
inclusion criteria: * had normal body mass index (ranged from 18.5 to 24.9 kg/ m2), * the school furniture workstations used by all subjects were all of wooden flat desks and benches. exclusion criteria: * suffering from respiratory or heart problems
gnrh-a on angiogenesis of endometriosis

Conditions: Angiogenesis; Endometriosis

Summary: purpose: neo-angiogenesis is necessary for adhesion and invasiveness of endometriotic lesions in women affected by endometriosis. vegf is one of the major components of angiogenesis and is part of the major pathway tf-par-2-vegf that leads to neo-angiogenesis. sp1 is a transcriptional factor that has lately been studied for its crucial role in angiogenesis, via a distinct pathway. we hypothesize that by blocking angiogenetic pathways we can repress endometriotic lesions. gnrh-agonists are routinely used, especially pre-operatively, in endometriosis. it would be interesting to clarify which angiogenetic pathways are affected and pave the way for further research over anti-angiogenetic effects on endometriosis. methods: we used qrt-pcr to study mrna expression levels of tf, par-2, vegf and sp1 in endometriotic tissues of women who underwent surgery for endometriosis and received gnrh-a \[leuprolide acetate\] preoperatively.

the subjects in this study were women of reproductive age. from september 2015 to december 2022, sixty women with known endometriosis \[stage 2 and 3\], were recruited. their mean age was 38 years. they were nulliparous and had a mean bmi of 27 kg/m2. the ovarian endometrioma, present in all the participants, was diagnosed by ultrasonography and/or magnetic resonance imaging. this was a prospective randomized follow up study with analysis of ovarian samples derived from gnrh agonists-treated and non-treated women before surgery. the randomization was performed by accessing a central internet-based randomization program. the random allocation sequence and the assignment of the participants to interventions were made by 2 of the authors \[a.k. and s.k\]. after enrollment, patients were divided into 2 groups . during laparoscopy, biopsy specimens of the ovarian endometrioma were collected. the staging of endometriosis was based on the rasrm classification system. in group b, surgery was performed during the proliferative phase of the menstrual cycle. all biopsy specimens were collected in accordance with the guidelines of the declaration of helsinki and with the approval of the ethical committee of the general university hospital of patras. informed consent was obtained from all women.

Eligibility criteria:
inclusion criteria: * reproductive age. * endometriosis \[stage 2 and 3\] * nulliparous exclusion criteria: * women who received any hormonal treatment within the 12 months before the surgical procedure * obesity bmi\>32kg/m2

Keywords: endometriosis angiogenesis gnrh-a vegf sp1
gallbladder cholesterolosis, body mass index and serum cholesterol and triglycerides

Conditions: Gallstones; Gallbladder Cholesterolosis

Summary: cholesterolosis is a common finding in biopsy specimens of gallbladders surgically removed for cholelithiasis. to the best of the investigators knowledge no study has analyzed the relationships of body mass index, serum cholesterol and triglycerides and gallbladder cholesterolosis. the purpose of this study is to analyze and find relations between gallbladder cholesterolosis, body mass index, serum cholesterol and triglycerides.

a prospective database including the following variables was filled out: * age * gender * diagnosis * weight * height * body mass index * histopathological results (biopsy) * serum cholesterol * serum triglycerides all elective patients older than 15 years of age submitted to cholecystectomy for symptomatic gallstones were included. plasma cholesterol and triglycerides levels were measured 5 to 7 days before surgery. only patients with chronic cholecystitis and with cholesterolosis according to the histology of the surgical specimen were included, we did not include any patient with acute cholecystitis or gallbladder cancer.

Eligibility criteria:
inclusion criteria: * patients submitted to elective cholecystectomy * histopathological report of gallbladder cholesterolosis * histopathological report of chronic cholecystitis * patients older than 15 years of age exclusion criteria: * patients younger than 15 years of age * pathological report missing from the hospital records

Keywords: gallstones gallbladder cholesterolosis serum cholesterol triglycerides body mass index
intraarticular dextrose prolotherapy for symptomatic knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the purpose of this research is to learn more about treating symptomatic knee osteoarthritis (oa) with an ultrasound-guided hypertonic dextrose injection. researchers would like to determine best practice for injection frequency and effectiveness of the dextrose injection for symptomatic knee oa.


Eligibility criteria:
inclusion criteria: * diagnosis of knee oa by clinical criteria (american college of rheumatology). * identification of knee osteoarthritis by a radiologist on an existing knee radiograph obtained within 3 years of enrollment. * moderate to severe knee pain for at least 3 months, defined as a score of ≥ 4 (on a 0-10 point numeric rating scale) in response to the question "what is the average level of your left/right knee pain in the past 3 months?". exclusion criteria: * pregnancy. * diabetes. * anticoagulation therapy. * history of total knee replacement. * prior knee prolotherapy or other regenerative product. * any knee injection within 3 months. * inflammatory (ra, gout, pseudogout etc.) or postinfectious knee arthritis. * daily use of opioid medication. * allergy or intolerance to study medication, corn allergy. * body mass index (bmi) greater than 40 kg/m\^2. * comorbidity severe enough to prevent participation in the study protocol.
endothelin-receptor blockade in coronary heart disease

Conditions: Coronary Vessels; Endothelins; Vascular Resistance

Summary: endothelin is a hormon that causes acute and chronic narrowing of heart vessels. the purpose of this study is to assess whether suppression of this activity by using two types of receptor antagonists can reduce this effect and thus improve blood supply of the heart muscle.

endothelin (et) is the most potent vasoconstrictor known and plays a major role in the development of coronary artery disease as well as in acute vasoconstriction. this effect is mainly mediated by the vascular et-a receptor, whereas the et-b receptor mediates vasodilation and cleavage of et. currently, there are both selective et-a antagonists and non-selective et-a and et-b antagonists under investigation. the aim of the study is to test the effect of et-receptor blockade on the vasoreagibility of epicardial and intramyocardial coronary arteries in patients undergoing cardiac catheterization. we randomly use the selective et-a receptor bq-123 (group a) and the combination of bq-123 and the et-b receptor antagonist bq-788 (group b). the tested infusion will be applied selectively into the assessed coronary artery by a special infusion catheter. to evaluate the morphometric changes we use quantitative coronary angiography to measure the diameter of the coronary artery before and after intracoronary infusion of the tested substances. furthermore we will use pressure wire to measure the hemodynamic conditions before and after infusion, thus evaluating the epicardial and the intramyocardial blood perfusion. comparison: coronary artery diameter as measured by quantitative angiography (minimal lumen diameter) and parameters indicative of epicardial and intramyocardial blood flow as determined by pressure wire (fractional flow reserver, coronary flow reserve, intramyocardial resistance) before and after et-antagonist infusion will be compared.

Eligibility criteria:
inclusion criteria: * coronary artey disease * stable angina pectoris * male and post-menopausal female patients * age above 19 years * able and willing to conform to the requirements of the study * provided written informed consent exclusion criteria: * severe focal coronary stenosis * visually calcified stenosis * aorto-ostial lesion location and unprotected left main stenosis * pre-menopausal female patients * diabetes mellitus * unstable angina pectoris and/or acute q-wave myocardial infarctaion within the past 72 hours * current vasoactive medication * previous percutaneous transluminal revascularization at the site of the target lesion * lesion which has extremely angulated segments \>90% * vessel with escessive tortuosity of the proximal segment * severe hypotension * severely reduced left ventricular function * severe carotid stenosis * patients with pace maker * patients with elevated liver enzymes * patients simultaneously participating in another device or drug study * inability of unwillingness to comply with the study protocol

Keywords: coronary heart disease endothelins coronary angiography blood flow velocity fractional flow reserve, myocardial
comparison of subcuticular suture versus surgical staples for closure of pfannenstiel skin incisions

Conditions: Pain, Postoperative; Gynecologic Surgical Procedures; Obstetric Surgical Procedures

Summary: this study compares methods of closure for pfannenstiel incisions commonly used during gynecological and obstetrical surgery. patients are assigned to closure by either surgical staples or a buried suture. information is collected on the day of surgery, post-operative day two and at the six-week follow up visit. the amount of pain and cosmetic result are compared. infection rates will also be monitored for the two groups. the study hypothesis is as follows: subcuticular (buried) sutures as compared to surgical staples lead to decreased post-operative pain and improved cosmetic result. infection rates are similar for both groups.

there is little evidence in the literature to guide the choice of closure material for pfannenstiel laparotomy. currently this decision is based primarily on physician preference. physicians differ greatly in their view on which is better. this is based on personal habit and experience and not on scientific evidence. specifically in the field of obstetrics and gynecology there has only been one randomized trial of approximately 60 patients undergoing cesarean section comparing subcuticular suture vs surgical staples for closure of their pfannenstiel skin incisions (frishman et al., 1997). this study showed that pfannenstiel skin incisions closed with subcuticular closure following cesarean section result in less postoperative pain and are more cosmetically appealing as compared to incisions closed with staples. this randomized controlled study will compare closure of pfannenstiel incisions using either subcuticular absorbable suture or surgical staples. it will examine two separate populations - those undergoing cesarean section and those undergoing gynecological surgery such as hysterectomy. these patient groups will be analyzed separately as their demographic characteristics tend to be quite different. the primary outcome will be postoperative pain. cosmetic result will be a secondary outcome. cosmesis will be rated both by the patient and the physician. infection rates are also of great interest although it is unlikely that this study will achieve adequate power to show a statistically significant difference in results. other outcomes of interest include overall patient satisfaction, total operating room time and length of hospital stay. patient's body mass index will also be recorded and analyzed to determine whether it affects results in both intervention groups. there will be a minimum of 144 patients total in the cesarean section group and 144 patients total in the gynecological surgery group - 72 randomized to staples and 72 randomized to subcuticular suture for each group. thus the entire study will involve approximately 288 patients.

Eligibility criteria:
inclusion criteria: * undergoing gynecological or obstetrical surgery * pfannenstiel skin incision

Keywords: wound closure pfannenstiel incision surgical staples subcuticular suture
a study of combination therapy with amivantamab and docetaxel in participants with metastatic non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the purpose of this study is to identify the recommended phase 2 (combination) dose (rp2cd) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (nsclc) in phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected rp2cd in participants with nsclc without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the phase 2 (expansion).


Eligibility criteria:
inclusion criteria: * participant must have histologically or cytologically confirmed nsclc and must have metastatic nsclc at the time of enrollment * participant must have at least 1 measurable lesion, according to recist v1.1, that has not been previously irradiated * may have brain metastases only if previously definitively treated, and participant is clinically stable and asymptomatic for \>2 weeks and is off or receiving low-dose corticosteroid treatment (\<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment * may have a prior malignancy (other than the disease under study) if the natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) * have an ecog performance status of 0 or 1 exclusion criteria: * for phase 2 only: participant has known oncogenic driver mutations (egfr, met, her2, alk, ros1, ntrk, braf, ret, or kras) as detected by local testing or by central ctdna testing * participant has received radiotherapy for palliative purposes less than 14 days prior to the first dose of study treatment * participant has: a.(or has a history of) leptomeningeal disease (carcinomatous meningitis); b. spinal cord compression not definitively treated with surgery or radiation. * medical history of (non-infectious) ild/pneumonitis, or has current ild/pneumonitis, or where suspected ild/pneumonitis cannot be ruled out by imaging at screening- participant has history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia) or has known allergies, hypersensitivity, or intolerance to: a. amivantamab or amivantamab excipients (refer to the amivantamab ib); b.docetaxel, docetaxel excipients or to other drugs formulated with polysorbate and paclitaxel
lipoprotein(a) levels in patients with atherosclerotic cardiovascular diseases in russia

Conditions: Atherosclerotic Cardiovascular Disease

Summary: this study has the purpose to answer how the lipoprotein(a) (lp(a)) level is distributed among atherosclerotic cardiovascular disease (ascvd) patients in russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (cvd) risk.

this study will consist of several phases (consecutive stages): phase i: a cross-sectional study of lp(a) level with ascvd patients phase ii: * a non-interventional, prospective, cohort study with the phase i patients * a cross-sectional study of lp(a) levels with relatives of phase i patients * a non-interventional, prospective, cohort study with patients' relatives

Eligibility criteria:
inclusion criteria: 1. written informed consent (signed and dated). 2. males and females aged ≥18 years. 3. presence of one of the following ascvds for at least 3 months within the 2 years prior to signing the informed consent to participate in this study: * history of mi; * history of is and/or tia; * ihd confirmed by coronary angiography (stenosis ≥50%); * any revascularization surgery (emergency or planned), including cabg, pci, carotid endarterectomy or carotid/intracranial stenting; * peripheral artery disease (intermittent claudication with ankle-brachial index ≤0.90 and/or lower limb amputation or revascularization in case of lower limb ischemia). exclusion criteria: 1. acute infectious and inflammatory diseases, such as covid-19, in the month leading up to the screening visit. 2. lp(a)-lowering therapy/methods (lp(a) apheresis with pcsk9 inhibitors, inclisiran prior to the screening visit) in the medical history before the screening visit. 3. participation in any interventional clinical study with investigational or marketed medicinal products at the time of enrollment. 4. participation in other real-world clinical studies. 5. stages 4 and 5 of chronic kidney disease (glomerular filtration rate ckd-epi \<30 ml/min/1.73 m2) and/or hepatic disease (total bilirubin: 2 × uln). other protocol-defined inclusion/exclusion criteria may apply.

Keywords: lipoprotein(a), ascvd, cardiovascular disease, cvd
evaluation of poc pulse-dose demand oxygen delivery for nocturnal hypoxemia

Conditions: Nocturnal Hypoxemia

Summary: the aim of this study is to describe the effect of the inogen rove 6 portable oxygen concentrator on peripheral oxygen saturation in adults receiving supplemental oxygen at night and examine whether the device can adequately maintain oxygen saturation during sleep.

the study design is a prospective, single site, single arm, open label, pilot study. the aim of this study is to describe the effect of the inogen rove 6 portable oxygen concentrator on peripheral oxygen saturation in adults receiving supplemental oxygen at night and examine whether the device can adequately maintain oxygen saturation during sleep, i.e., achieve target with initial titration setting and/or with any needed adjustments of setting.

Eligibility criteria:
inclusion criteria: 1. subjects may be of any gender 2. subject's age must be 40 - 80 years 3. subjects must have a current prescription for nocturnal oxygen \< 3 l/min continuous or current use of a portable oxygen concentrator. exclusion criteria: 1. subject is using any ancillary medical device(s) that may interfere with the operation of or data interpretation from the inogenone device (such as cpap/bipap, niv). 2. subjects with nasal obstruction 3. subjects taking any drugs that affect respiratory center drive 4. subject has an acute illness or hospitalization within the last 30 days 5. subject has a change in medication within the last 15 days 6. subject is currently receiving respiratory stimulant medications (such as acetazolamide, medroxyprogesterone, doxapram, theophylline/aminophylline, protriptyline and buspirone) 7. subject has significant comorbidities that in the opinion of the investigator would interfere with outcomes and/or study conduct 8. subject's prescribed treatment is in conflict with study procedures 9. subjects with any unstable disease

Keywords: hypoxemia, oxygen
detrol la in men with overactive bladder.

Conditions: Overactive Bladder (OAB)

Summary: an interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints, quality of life and patient treatment satisfaction. patients included in the study must have symptoms of oab (frequency of at least 8 per day and urgency of at least 1 episode per day confirmed by bladder diary). patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.


Eligibility criteria:
inclusion criteria: * symptoms of oab (frequency more than 8 per day and urgency more than 1 episode per day confirmed by bladder diary) exclusion criteria: * significant hepatic or renal disease, history of radiation treatment